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ABSTRACT
Purpose The safe and functional delivery of progesterone
through the vaginal route remains an unmet clinical need. The
purpose of this work is to prepare a new progesterone (P4) gel
for vaginal application using a thermosensitive mucoadhesive
polymer, glycol chitin (GC).
Method Thermogelling, mucoadhesive, mechanical, and viscoelas-
tic properties of GC and the new formulation were evaluated using
rheometry. In vitro release profile and the bioactivity of P4 were
determined using vaginal fluid simulant (VFS) pH 4.2, and PR-
reporter gene assay, respectively. In vitro safety of the formulations
was tested using (VK2/E6E7) vaginal epithelial cell line and
Lactobacillus Crispatus. Finally, in vivo safety and the efficacy of this
formulation were evaluated using an endometrial hypoplasia mouse
model.
Results Results shows the aqueous solution of 5%; (w/v) GC
loaded with 0.1%; (w/v) P4 prepared in pH 4.2, (GC-P4), forms
a thermosensitive mucoadhesive hydrogel and can maintain stable
physical properties at 37°C. GC-P4 gel release 50% of P4 in 4 h
after exposure to VFS, and no significant decrease in % viability of
VK2/E6E7 or Lactobacilluswas found after exposure to 5%GCor
GC-P4. GC-P4 does not exhibit obvious toxicities to vaginal
tissue in vivo even after repeated application. Efficacy studies
indicated that GC-P4 was capable of preventing the progression
of simple endometrial hyperplasia (SEH) to complex atypical
endometrial hyperplasia (CAEH) in vivo.
Conclusions Results indicates that GC-P4 retains many charac-
teristics for an effective vaginal delivery system for P4. Therefore
we believe that GC-P4 formulation is a promising alternative to
current vaginal P4 formulation.
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ABBREVIATIONS
CAEH Complex atypical endometrial hyperplasia
CFU Colony forming unit
COS Critical oscillatory stress
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Introduction
Progesterone (P4) is a female steroidal hormone that plays a
crucial role in maintaining normal physiology of the female
reproductive system. P4 is mainly involved in benign, cycle-
dependent tissue proliferation of the uterus, ovulation, im-
plantation of the fertilized ovum, and maintenance of preg-
nancy (1). Other physiological actions of P4 include the pro-
liferation of normal breast tissue, protection against bone loss,
as well as regulation of sexual responsive signals in the brain
(1). Based on its broad impact, the therapeutic use of P4 has
been applied in the management of various female reproduc-
tive conditions such as the prevention of preterm birth, luteal
phase support, and in hormonal replacement therapy (HRT)
(2–4). Furthermore, the antiestrogenic effect of P4 on the
endometrium led to the emergence of P4 therapy as a part
of fertility–sparing treatment for endometrial hyperplasia
(EH) and primary endometrial carcinoma (EC) (5).
Various different options of P4 administration and formu-
lation are available. Oral administration of bio-identical P4
provides convenient dosing. However, poor bioavailability
due to the hepatic first pass effect provides only low endome-
trial P4 concentrations (6). On the other hand, synthetic P4
known as progestins, are commonly associated with undesir-
able side effects ranging from acne and water retention to
depression (7). To better facilitate the cellular absorption,
intramuscular (IM) injections of P4 have become a popular
administration route. Yet, pain with injection, irritation at the
injection site, infections and possible abscesses leading to
neuropathies in some cases, can reduce patient compliance,
and therefore therapeutic efficacy (8). In light of the afore-
mentioned limitations, the vaginal route has gained accep-
tance as a viable drug delivery route, especially in the man-
agement of obstetrical and gynecological conditions (9,10). In
addition, the vaginal administration of P4 exhibits a preferen-
tial absorption and distribution to the uterus based on the
uterine first pass effect, a direct transport mechanism for drugs
from vagina to the uterus (11,12).
Although vaginal P4 formulations such as suppositories
and creams show clear advantages over other routes including
the avoidance of the hepatic first pass effect, ease of adminis-
tration, and the provision of site-specific treatments, currently
available P4 vaginal formulations exhibit major drawbacks (6).
The challenging vaginal environment including body temper-
ature (37°C), a more acidic pH (4.5–5.5), vaginal secretions,
and the self-cleansing mechanisms lead to the leakage of
almost all formulations resulting in significantly decreased
vaginal residence times, local tissue irritation and inflamma-
tion, more frequent yeast infections, and most importantly the
loss of active ingredients responsible for an unsatisfactory
therapeutic effect (2,13).
Recently, thermosensitive polymers possessing a reversible
sol–gel transition behavior in aqueous media have been uti-
lized for vaginal delivery of various drugs such as 5-
fluorouracil and metronidazole (9,10). Such gels were found
to provide a convenient and effective treatment method,
especially if combined with mucoadhesive agents (9). In a
previous report, we introduced glycol chitin (GC), which has
proven to be a suitable candidate for various biomedical
applications including its use as an injectable drug delivery
vehicle and a potential new material for tissue engineering
purposes (14). In addition, chitosan amphiphilic derivatives
are known to enhance the solubility of hydrophobic agents
(15,16).
Based on the aforementioned characteristics, we report for
the first time the application of GC in vaginal drug delivery
and it usage as a carrier for P4. We hypothesized that GC-P4
provide a safe, effective, and a better alternative to currently
available vaginal P4 formulations. In order to confirm our
hypothesis, several rheological, release profiles, as well as




Progesterone was purchased from Spectrum (Gardena, CA,
USA). Glycol chitosan (DP≥400), acetic anhydride (99.5%),
and Porcine stomach derived Mucin type III were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Crinone® gel was
purchased from Watson Pharmaceutics (Morristown, NJ,
USA). Gynol II® was purchased from Revive (Madison, NJ,
USA). All other chemical reagents used were of analytical
grade and used without further purification.
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Cell Culture
VK2/E6E7, Human vaginal epitheliums cell line (CRL-2616)
and 293 T human embryonic kidney cells line (CRL-3216)
were purchased from the American Type Cell Culture collec-
tion (ATCC, Manassas, VA). VK2/E6E7 were cultured
in Keratinocyte-Serum Free medium (Invitrogen, Grand
Island, NY, USA), supplemented with 0.1 ng/ml human
recombinant epidermal growth factor, 0.05 mg/ml bo-
vine pituitary extract, 100 units/ml penici l l in,
100 μg/ml streptomycin, and additional calcium chlo-
ride of 0.4 mM. 293 T were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 100 units/ ml penicillin,
and 100 μg/ml streptomycin. Cells were grown and routinely
maintained at 37°C in 10-cm2 culture dishes. Lactobacillus
crsipatus was purchased from ATCC and grown in an ATCC
medium 146 Lactobacillus MRS agar/broth (BD, Sparks,
MD, USA) at 37°C.
Animal Studies
Female Nu/Nu mice (6–8 week old) were obtained
from Jackson Laboratory (Bar Harbor, ME USA).
Mice were housed at the Center for Comparative
Medicine Animal Facility and treated following ap-
proved Institutional Animal Care and Use Committee
(IACUC) protocols and guidelines.
Glycol Chitin (GC) Hydrogel for Vaginal Application
Preparation of Glycol Chitin (GC)
GC with ≈90% degree of acetylation (DA) was chosen in this
study and was synthesized and characterized as described
previously (14). The synthetic method and results are
described on Supporting Information and (Fig S1). GC
solution was prepared according to the modified cold
method (17). Briefly, GC was slowly added to cold
citrate phosphate buffer (4°C, 0.1 M, pH 4.2) under
gentle mixing and allowed to dissolve completely for
24 h at 4°C.
Effect of Concentration and pH on GC Gelation
To test the effect of concentration and pH on GC gelation
temperature (Tgel), GC solutions were prepared at various
concentrations of 5, 6, and 7%; (w/v) at pH 4.2. Tgel were
determined by using a stress-controlled rheometer (AR 550;
TA instrument, DE, USA). The rheometer was equipped with
20 mm 4° steel cone geometry. Frequency and oscillatory
stress were maintained with constant values of 1 Hz and
5 Pa, respectively. The temperature sweep analyses were
conducted in the range of 15–45°C with a heating rate of
1°C/min. The gelation point was considered to be at the
crossover point between G′ (elastic modulus) and G″ (viscous
modulus). Effect of pH on gelation was measured on the GC’s
concentration showing a Tgel within the acceptable tempera-
ture range for mucosal application between (30–36°C) at pHs
of 4.2, 6 or 7.2 (10).
Rheological Examination of GC Mucoadhesive
Characteristic
To determine mucoadhesive property of GC, a GC-mucin
mixture was prepared at pH 4.2. The final concentrations of
mucin and GC in the solutions were 4 and 5%; (w/v) respec-
tively (18). GC and mucin were mixed prior to rheological
evaluation. The linear viscoelastic region (LVR) for each
sample was determined through a strain sweep measurement
at a constant frequency of 1Hz and 37°C. Frequency
sweep analysis was performed at a range of 0.1–10 Hz
within the LVR of the gel (19). Mean G′ for samples
were extracted from frequency sweep spectra. Positive
values of the absolute synergism parameter (ΔG), which is a
equal to the interaction between polymer and mucin, is an
indicative of mucoadhesion (20). The following equation was
used to calculate ΔG (20):





′ are the elastic moduli for polymer-mucin
mixture and the polymer alone, respectively. The contribu-
tion of the mucin elastic modulus (Gm
′ ) was neglected in the
equation since it was relatively low.
Glycol Chitin-Progesterone (GC-P4) Hydrogel
Solubility of P4 in GC Solutions
To test the solubility of P4 in GC, P4 was mixed in GC
solutions (1–5%; w/v) and stirred for 24 h at 4°C. The
clear GC-P4 solution collected from centrifugation (12,
000 RPM, 4°C) was used to determine the amount of
solubilized P4 employing reversed phase (RP)-HPLC
(Agilent Chemstation for LC/MS system, CA, USA)
equipped with a C18 column at 254 nm (21). A mixture
of methanol/water (80:20; v/v) was used, as the mobile
phase at a flow rate of 1 ml/min.
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Preparation of GC-P4 Hydrogel
GC-P4 gel was prepared by adding P4 into the 5% GC
solution (pH 4.2) in a concentration that exceeded it solubility
and stirred for 24 h at 4°C. The final P4 concentration in GC
solution was of 0.1%; (w/v). Osmolarity of GC-P4 was 358.16
±6.5 mmol/kg. Tgel for GC-P4 hydrogel was assessed using
the same method described earlier.
Mechanical Characteristics of GC-P4 Hydrogel
Dynamic Oscillatory Rheology
To determine the mechanical spectra of GC-P4 hydrogel, an
oscillatory stress sweep step was conducted using a stressed-
controlled rheometer equipped with 20 mm 4° steel cone
geometry. One hundred and fifty microliter of GC-P4 was
placed on the Palter plate. The sample was allowed to equil-
ibrate for 5 min at room temperature 25°C as well as 37°C.
An oscillatory stress step was conducted in the ranges of 0.5–
1000 Pa at a frequency of 1 Hz. The critical oscillatory stress
(COS), the maximum stress at which the linear value of G′ is
disturbed, was obtained from the stress step spectra (22).
Mechanical spectra of Crinone® and GC-P4 were also deter-
mined to compare the strengths of the two gels in vaginal like
environment. The value of stress representative of the visco-
elastic region of GC-P4 was used in the oscillatory frequency
analysis (5 Pa). Oscillatory frequency step was conducted in a
frequency range of 0.1–10 Hz at 25 and 37°C (19,23).
Steady Shear Viscosity (Flow rheology)
To determine flow behavior of GC-P4, a shear step was
conducted in the biological relevant shear of 0.1–100 s−1,
resembling shear exposed by passive seeping of vaginal epi-
thelium all the way to shear during coitus, respectively
(23–25). Frequency was kept constant at 1 Hz. The sample
was allowed to equilibrate for 5 min at 25 and 37°C prior
initiation of the shear step.
Rate of GC-P4 Gelation
To determine the time required for GC-P4 to transform to a
gel state at body temperature, a time sweep analysis was
conducted. Time sweep analysis was set for 10 min at a
constant frequency of 1 Hz in addition of 5 Pa oscillatory
stress. The sample was set to equilibrate for 5 min at 15°C in
the conditioning step to assure the liquid state of GC-P4
before initiating the time sweep. At the onset of time sweep,
the temperature was raised to 37°C and gelation time was
recorded.
GC-P4 Hydrogel in Biologically Relevant Fluids
To determine rheological behavior of GC-P4 after dilution
with fluids that usually presents in the vagina, viscosities and
the effect of dilution on gelation were evaluated. Vaginal fluid
simulant (VFS) of pH 4.2 and seminal fluid simulant (SFS) of
pH 7.7 were prepared as described previously (26,27). GC-P4
hydrogels were diluted with VFS in a biologically relevant
ratio of (1:4; VFS: GC-P4) and (1:6; VFS: GC-P4) (28). A fresh
set of GC-P4 samples were prepared and diluted with SFS in a
biologically relevant ratio of (1:1; SFS: GC-P4) (28). For the
measurement of gel behavior following dilution, gel samples
were left on the rheometer platform to equilibrate for 60 s
prior to being mixed with either VFS or SFS. Steady shear
viscosity step and time sweep analysis were conducted as
described earlier.
In Vitro Release of P4 from GC-P4 Hydrogel
Swelling/Erosion of GC-P4 Hydrogel
To study the mechanisms of in vitro P4 release from the GC-
P4, change in hydrogel weight as function of time following
VFS exposure was measured. One ml of GC-P4 was placed
into screw capped vials and incubated at 37°C. Following gel
formation, 0.75 ml VFSs was placed over GC-P4. Vials were
then placed on the platform of a MaxQ 4450 Benchtop
Incubating Shaker (Thermoscientific, IA, USA). The incuba-
tion temperature was maintained at 37°C. Samples were
subjected to a rotation speed of 70 rpm (providing shear rate
of 50 s−1). At predetermined time intervals, VFSs were re-
moved by pipette and replace by a fresh solvent. GC-P4 were
weighed at each time intervals using a AG104 analytical
balance (METTLE TOLEDO, Columbus, OH). The
amounts of VFS removed at each time were used to further
analyze the percentage of P4 released from the hydrogel.
Determination of P4 Release from GC-P4 Hydrogel
To analyze the amount of P4 release from GC-P4 hydrogel,
P4 was extracted from VFS using diethyl ether. Briefly, in a
fume hood, 3 ml of diethyl ether were added to the VFSs.
Samples were vortexed for 1 minutest at room temperature
and then placed in −20°C until complete freezing of the
aqueous phase occurred. The organic layer was then removed
and the samples were kept in a fume hood until complete
evaporation of the organic phase. Samples were then
suspended in 80 v/v% ethanol and the amount of P4 was
determined (21). Quantitative determination of P4 was con-
ducted using a linear calibration curve between the range of
1.96–62.5 μg/ml and a 0.99 correlation coefficient.
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Reporter Gene Assay
To confirm the bioactivity of P4 released from GC-P4 system,
the ability of P4 to induce Progesterone receptor (PR)-
signal transduction pathways was performed. Briefly,
239 T cells were seeded in a density of 1.5×106 cells
/ well in a 6-well plate. A plasmid containing P4
responsive elements (PRE) fused to firefly luciferase
(Cignal reporter assay kit, QIAGEN, CA, USA) was
transfected into 239 T (500 ng /well). Transfection
was carried out using FuGENE® 6 Transfection
Reagent (Promega, WI, USA). 24 h post-transfection,
cells were treated with either P4100nm, GC-P4100nm,
GC, or no treatment for 18 h. Luciferase activity was
measured using Dual-Luciferase Reporter Assay System
(Promega, WI, USA) according to manufacture’s in-
struction. Results were represented as Luciferase activ-
ity normalized to Renilla luciferase.
In Vitro Safety and Toxicity of GC-P4 Hydrogel
MTT 3-(4,5-dimethylthiazol-2-yl)
-2,5-diphenyltetrazolium Bromide Assay
To determine GC biocompatibility with vaginal epithelium,
VK2/E6E7 cells were seeded in 96-well plate at a density of
5×103 cell/well and incubated for 24 h in a volume of 100 μl
media/well. Serial dilutions of GC in citrate-phosphate buffer
(0.1 M, pH 4.2) were added to the cells and incubated for
another 24 h. After exposure, 20 μl of 2.5 mg/ml MTT
(Invitrogen, OR, USA) in PBS was added to the cells. The
cells were incubated with MTT for 4 h 37°C. MTT solutions
were completely removed and 100 μl DMSO was added to
solubilize formazan crystals. Absorbance was measured at
540 nm using Spectramax 250 microplate reader (Molecular
device, CA, USA). Percent viability was calculated from
(OD540 sample / OD540 control)×100, referring to GC treat-
ed and non-treated cells.
Lactobacillus Viability Assay
To assess the effect of GC on the sustainability of an intact,
normal vaginal flora, the viability of Lactobacillus crispatus after
the exposure to GC was determined. Bacteria were seeded in
a density of 107 colony formation units (CFU) / 100 μl in 96-
well plates and incubated with 100 μl serial dilutions of GC at
37°C for 24 h. After 24 h incubation, a 20 μl MTS [3-(4,5-
dimethyl thiazole-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fonyl) 2H-tetrazolium (Promega, Madison, WI, USA) reagent
was added to each well. Absorbance was measured at 490 nm
and the percent viability was calculated from (OD490 sample/
OD490 control)×100, which refers to GC treated and non-
treated bacteria. To confirm the safety of GC in the concen-
trating used for the GC-P4 formulation, the ability of
5% GC as well GC-P4 to inhibit the growth of
Lactobacillus on an agar plate was tested. A scrap of
Lactobacillus crispatus from bacterial broth was directly
spread on an MRS agar plate. Each plate was divided
into four quarters and 250 ul of the tested material was
placed in the center of each quarter. Plates were incu-
bated for 24 h at 37°C. The effect of 5% GC and GC-
P4 on bacterial growth were evaluated and compared to
the effect of both Gynol II® (nonoxynol-9) and
Crinone®.
Clonogenic Assay
Human VK2/E6E7 were seeded in six well plates
(Transwell®, Costar, NY, USA) in a density of 2000 cells/
well. Cells were incubated in 2 ml Keratinocyte-Serum Free
medium until complete cells attachment. Cells were then
treated with either 5% GC, GC-P4200μg, P4200μg, Gynol II®
as a positive control, or Crinone®200μg, through a 0.4 μm
polyester transwell membrane for 24 h. In addition, one group
of cells was left untreated and served as a blank. Transwells
were then removed and cells were cultured for additional
7 days until the formation of visible colonies. Colonies were
then fixed for at least 30 min with a 6% glutaraldehyde and
0.5 crystal violets mixture. Wells were rinsed under running
tap water and numbers of blue visual colonies were quantified
with Image J 1.44o software (N.I.H., Bethesda, MD, USA)
(size range of 2~200 μm).
In Vivo Safety and Efficacy of GC-P4 Hydrogel
In Vivo Safety of GC-P4 Gel to Vaginal Epithelium
To investigate the safety of GC-P4 gel when applied to mouse
vaginal epithelium in vivo, mice were divided into three groups
(n=2), anesthetized by IP injection withXylazine-Ketamine at
dose of 0.1 ml / 10 g and treated vaginally with either GC-P4
gel, Gynol II® (positive control), or phosphate buffered saline
(PBS) (negative control) once a day for three consecutive days.
After 24 h of administering the last dose, all animals were
sacrificed and vaginal tissues were trimmed and fixed in 10%
formalin for 48 h. Tissues were dehydrated in 70% ethanol
and send to Associated Regional and University Pathologists
(ARUP) at the University of Utah for Hematoxylin and Eosin
staining (H&E). Histology of vaginal tissues for both treated
and control animals were examined by two independent
pathologists, using light microscopy at the department of
Pathology, University of Utah.
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In Vivo Efficacy of GC-P4 Gel in Estrogen (E2) Induced
Endometrial Hyperplasia (EH) Mouse Model
6–8 week old female Nu/Nu mice were divided in to three
groups and anesthetized. Doses of subcutaneous estrogen (E2)
were administered to mice in all groups to induce EH. One
group ofmice did not receive E2 therapy and served as disease
negative control. After 4 weeks of E2 treatment and
confirmation of simple endometrial hyperplasia (SEH)
through histology, one group of animals, which received
E2 therapy, received daily intravaginal GC-P4 (60 μg/
day) treatment for 2 weeks by restraining the mice in
rodent restrainer. The second group of E2 treated mice,
received no P4 treatment and served as disease positive
control. In 24 h of administering the last GC-P4 dose,
animals were sacrificed and uterine tissues were
trimmed, handled as mentioned earlier, and send to
ARUP for H&E. Histology of GC-P4 treated and non-
treated mice uteri were examined by two independent
pathologists using light microscopy at the department of
Pathology, University of Utah.
Statistical Analysis
Statistical analysis and plotting graphs were performed using
GraphPad Prism software (GraphPad Software Inc. San
Diego, CA). All experiments are conducted in triplicate unless
indicated otherwise. Results are expressed as mean ± SEM,
and P<0.05 was considered significant.
Results
Glycol Chitin (GC) Hydrogel for Vaginal Application
Although vaginal P4 administration has demonstrated prom-
ising potency for many obstetrical and gynecological condi-
tions when compared to other routes (oral and IM), environ-
mental limitations such as acidic pH and the abundance of
mucin in the vagina are challenging when aiming at the
broader clinical translation of vaginal drug delivery. To con-
firm that GC hydrogel is capable to successfully overcome
these challenges, we began the characterization by first mea-
suring the 90%DAGCs Tgel as a function of concentration or
pH. Ninety percent DAGCwas chosen in this study based on
its ability to form a low viscosity solution in room temperature,
which easy to handle and to corporate drug into, and having a
Tgel near body temperature using minimum polymer concen-
tration (14). Other DAGC, i.e. 80%, was tested in the polymer
selection process, however showed either no gelation in low
concentration, or give high Tgel (>40°C) in higher polymer
concentration (Figure S2). Tgel for GC was found to decrease
with increasing GC concentration, indicating 30.9±1.6°C,
28.2±1°C, and 23.1±1.3°C, at 5, 6, & and 7%, respectively
(Fig. 1a, Figure S3). In addition, the Tgel at 5% demonstrated
30.9±1.6, 26.5±2.9, and 15±1.3°C at a pH of 4.2, 6, and
7.2, respectively (Fig. 1b, Figure S4). Rheological analysis of
GC demonstrated a positive rheological synergism parameter
(ΔG>0) that existed between GC and mucin under physio-
logical pH (~4.2) indicating its mucoadhesive capability as
shown in Fig. 1c.
Glycol Chitin-Progesterone (GC-P4) Hydrogel
Water-soluble amphiphilic polymers have been frequently
studied for solubilization of hydrophobic drugs. Therefore,
we tested the GC solubilizing capacity of P4. P4 solubility was
found to proportionally increase with increasing GC
concentrations reaching 148.4±13.8 μg/ml in 5% GC
(Fig. 2a). This did not exceed the solubility of P4 when
using other formulations such as a mixture of PEG-
400/water (50:50 v/v) (29). To achieve therapeutically
relevant amounts, we further increased the amount of
P4 loaded within the gel, and P4 was added to 5% GC
solution in a concentration that exceeded its solubility.
Five percent GC solution containing P4 0.1%; (w/v) at
pH 4.2, which will be referred to as GC-P4 in the rest
of this manuscript, demonstrated a slight increase in Tgel
from 30.9±1.6°C to 34.3±1.6°C (Fig. 2b), which was statis-
tically non-significant (NS).Moreover, GC-P4 formed a stable
hydrogel in several seconds within vaginal (body) temperature
(Fig. 2c).
Mechanical Characteristics of GC-P4 Hydrogel
Confirming suitable mechanical characteristics equipping our
material with necessary properties to withstand the vaginal
environment, we studied the dynamics of GC-P4 rheological
properties in 25 and 37°C. Unlike at 25°C, GC-P4 revealed a
solid-like behavior with a rigid three dimensional microstruc-
ture under oscillatory stress ranging from 0.5 to 100 Pa in
37°C (Fig. 3a). When measuring critical oscillatory stress
(COS), GC-P4 formed a 1.5 times firmer gel than Crinone®
as shown in Fig. 3b. In addition, GC-P4 had a dominant
elastic property (G′ > G″) during frequency sweep analyses at
37°C (Fig. 3c) and indicated a tan δ = G″ / G′ < 1 as shown in
Fig. 3d. Where at 25°C, GC-P4 showed a typical liquid
material frequency spectra of G′ < G″, and frequency depen-
dent viscoelastic moduli.
GC-P4 Hydrogel in Biologically Relevant Fluids
Viscosity profiles showed that GC-P4 hydrogel presented a
pseudoplastic non-Newtonian behavior (shear thinning) with a
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biological relevant shear rate at 37°C (Fig. 4a). A significant
reduction in the viscosity of GC-P4 occurred at 25°C. Under
the influence of relevant biological fluids, GC-P4 showed a
slight decrease in viscosities under dilution with VFS (Fig. 4a).
However, as expected the viscosity of GC-P4 was significantly
decreased after the dilution with a SFS (Fig. 4b). Time sweep
analyses also showed destabilized viscoelastic moduli of GC-
P4 and a reduction in the magnitude between G′ and G″when
diluted with SFS (Fig. 4d). Mimicking prevalent physiological
conditions, GC-P4 diluted with VFS clearly yielded a stable
gel with constant viscoelastic moduli (Fig. 4c). GC-P4 was
capable of maintaining this stable gel state over 12 h showed
in (Figure S5)
In Vitro Release of P4 from GC-P4 Hydrogel
To determine the mechanisms of P4 release from GC-P4 and
estimate the gel durability, the hydrogel was exposed to VFS
at 37°C, and a shear of 50 s−1 (30). GC-P4 exhibited a 20%
increase in weight, which occurred within the first 30 min of
exposure, followed by a weight decrease. Weight decrease
reached up to 50% of GC-P4’s original weight following four
hours of exposure to VFS (Fig. 5a). Consequently, 50% of P4
was released from the hydrogel within the same amount of
time (Fig. 5b).
In addition we also investigated the bioactivity of the re-
leased P4 by progesterone receptor (PR) reporter assay cap-
turing only active P4 binding to PR. P4 released from GC-
P4100nM showed comparable activity with free P4100nM and
also demonstrated significant increase in PR reporter activity
compared to P4 non-treated and 5% GC only treated cells
(Fig. 5c).
In Vitro Safety and Toxicity of GC-P4 Hydrogel
To assess the safety and toxicity of GC-P4 as a vaginal drug
delivery system, cellular and microbial toxicity of GC and
GC-P4 to human vaginal epithelial cells as well as normal,
physiological vaginal flora were measured. MTT assays
showed no toxicity towards the human vaginal epithelial cell
line (VK2/E6E7) following exposure to different GC concen-
trations, indicated by (%) viability ranging from 84.4±15.8 to
107±22.3 (NS) when compared to untreated control cells
(Fig. 6a).
Lactobacilli act as gatekeepers for the vaginal ecosystem and
play a crucial role in protecting the vaginal environment from
Fig. 1 Glycol chitin (GC) hydrogel for vaginal application. (a) GC Tgel, at pH 4.2 decreased by increasing polymer concentration, and (b) environmental pH in
case of 5 wt % GC. (c) 5% GC retained mucoadhesive properties detected by a positive value of the interaction parameter ΔG and a Gmix
′ >GGC
′ .
Fig. 2 Glycol chitin-Progesterone (GC-P4) hydrogel. (a) Solubility of P4 in GC solutions. P4 solubility proportionally increased with increasing GC concentration,
(n=4). (b) 0.1%, (w/v) P4 loaded into 5%GC at pH 4.2 (GC-P4) maintains a Tgel near body temperature. (c) Gelation of GC-P4 within seconds after exposure
to vaginal temperature (37°C).
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pathogens. MTS assays were performed to evaluate lactobacillus
viability following exposure to various GC concentrations. GC
did not impact viability of Lactobacilli showing (%) viability
ranging from 95.6±3.7 to 106.4±1 (NS) (Fig. 6b). Further, there
was no effect on Lactobacillus growth on the agar plate after
exposure to 5% GC or GC-P4. However, Crinone®
Fig. 3 Mechanical characteristics of
GC-P4 hydrogel. (a) Stress sweep
analysis for GC-P4 gel at 25 and
37°C. (b) COSGC-p4 >
COSCrinone® indicating that GC-P4
gel is more resistance to external
stress, at 37°C. (c) Frequency
spectra in 37°C indicated that GC-
P4 gel exhibited elastic properties in
vaginal environment, unlike in
25°C. (d) tan δ = (G″/ G′) < 1 for
most frequency range for GC-P4 in
37°C typical for elastic-solid
materials.
Fig. 4 GC-P4 hydrogel in
biologically relevant fluids. (a) GC-
P4 presented a non-Newtonian
viscosity (shear thinning) in shear
rate of 0.1–100 s−1 37°C, and a
significant reduction of GC viscosity
at 25°C. (b) GC-P4 viscosity non-
significantly decreased after 1:6
dilution with VFS and significantly
decreased after 1:4 dilution. (c)
Dilution with SFS had a greater
impact on GC-P4 viscosity. (d)
Representative figures of GC-P4
time sweep analyses after dilution
with biological relevant fluids (n=2).
No effect on gel quality occurred
after 1:4 dilution of GC-P4 with
VFS, however, a decrease in gel
quality was found after 1:1 dilution
with SFS detected by unstable and
closer G′ and G″ values.
Formulation of Progesterone with a Thermosensitive Hydrogel 2273
and Gynol II® inhibited the growth of bacteria on the
agar plate (Figure S6).
In addition, clonogenic assays demonstrated that the
number of VK2/E6E7 cell colonies following exposures
to 5% GC was comparable to number of colonies in
the non-treated group. Although there was a slight
decrease in the number of VK2/E6E7 colonies treated
with GC-P4, the formation of colonies were significantly
reduced after treatment with Crinone® or Gynol II®
(Fig. 6c, Figure S7).
Fig. 5 In vitro release profile and
bioactivity of P4 released from GC-
P4 hydrogel. (a) Swelling of GC-P4
gel occurred within the first 30 min
after gel exposure to VFS at 37°C,
followed by decreased in weight
(erosion) (n=4). (b) Up to 50% of
P4 dose was released within 4 h of
exposure to VFS at 37°C (n=4). (c)
Increase in PR transcriptional activity
after treatment with GC-P4100nM
measured in RLU with no
significance different to RLU of
P4100nM treated cells.
Fig. 6 In vitro safety and toxicity of
GC-P4 hydrogel. (a) MTTassays
indicated no difference in percent
viability in VK2/E6E7 cell after
treatment with GC solutions. (b)
No difference between % viability
of Lactobacillus crispatus after
treatment with different
concentration of GC compared to
non-treated cells. (c) VK2/E6E7 cell
lines retained their ability to form
colonies after treatment with 5%
GC and GC-P4200μg gel compared
to P4200μg alone, Gynol II®, and
Crinone®200μg.
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In Vivo Safety and Efficacy of GC-P4 Hydrogel
To evaluate the safety and efficacy of GC-P4 following vaginal
administration in vivo, GC-P4 was evaluated in a mouse mod-
el. Six to eight week old female Nu/Nu mice were repeatedly
treated by vaginal administration of either GC-P4, Gynol II®
(positive control), or PBS (negative control). Histopathological
tissue evaluation was determinedas study endpoint.Within 24 h
following the last dose, animals were sacrificed, tissues were
harvested and vaginal epithelium underwent H&E staining
followed by independent histopathological evaluation through
two different anatomical pathologists. GC-P4 was determined
to be safe to administer to murine vaginal epithelium in vivo.
Only negligible, non-significant, transient signs of acute inflam-
mation were observed when compared to a control group
treated with PBS (Fig. 7a top and bottom). In contrast, treat-
ment with Gynol II® showed ubiquitous signs of chronic vag-
inal tissue inflammation accompanied by massive death of
squamous cells as well as a significant increase in neutrophils
were observed (Fig. 7a middle).
To further determine the efficacy of GC-P4 in vivo, we
designed and developed an E2 induced EH mouse model in
which mice were exposed to a continuous dose of exogenous
E2 over time. Female 6–8 week old Nu/Nu mice were
assigned randomly to receive no E2 or GC-P460μg (normal
endometrium), subcutaneous (s.c.) E2 only (disease control), or
s.c. E2 followed by GC-P460μg (treatment group). GC-P460μg
was administered vaginally once daily for 2 weeks after
confirming the successful development SEH. Within 24 h
after receiving the last dose mice were sacrificed.
Endometrial tissues were harvested and underwent H&E
staining followed by histopathological evaluation. As expect-
ed, normal, untreated mouse endometrium showed small
tubular glands, some in clusters, but overall with abundant
intervening stroma representative of healthy endometrium.
Occasional mitotic figures were noted in endometrial glandu-
lar cells, consistent with proliferative phase endometrium
(Fig. 7b top). Endometrial samples derived from mice that
were exposed to E2 showed the development of markedly
crowded glands with complex architecture, lined by cells with
Fig. 7 In vivo safety and efficacy of
GC-P4 hydrogel. (a) Hematoxylin
and Eosin staining (H&E) PBS (Top)
with Intact squamous cells
(Keratinocytes) and rare Neutrophil
cells, Gynol II® gel (Middle) arrows
indicate massive cell death of
squamous cells (Keratinocytes), and
GC-P4 (bottom) arrow indicate
minimal cell death of Keratinocytes,
X200. (b) Normal, murine
endometrium demonstrates small
tubular glands, some in clusters, but
overall with abundant intervening
stroma X100 (top). E2 Effect, no
GC-P4 treatment X400 (middle)
demonstrating complex atypical
hyperplasia. Following initial daily
treatment with vaginal GC-P460μg
for 2 weeks, the features are
consistent with simple non-atypical
hyperplasia X200 (bottom). Scale
bar=100um.
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enlarged, atypical nuclei exhibiting a loss of polarity and
variably conspicuous nucleoli, characteristic of complex atyp-
ical endometrial hyperplasia (CAEH) (Fig. 7b middle). The
endometrium of mice treated with GC-P460μg following E2-
based establishment of non-atypical SEH contained crowded,
cystically dilated glands lined by cytologically unremarkable
proliferating glandular cells, all characteristic for SEH (Fig. 7b
bottom). Tissue histology identified clear differences in be-
tween GC-P460μg treated and non-treated hyperplastic
endometrium
Discussion
The goal of this study is to improve and optimize vaginal P4
delivery by designing a new thermosensitive, mucoadhesive
gel using GC, a chitosan derivative, as the delivery platform.
The results demonstrate that GC-P4 is a promising P4-
delivery system suitable for vaginal application. GC-P4 gel is
stable in a vaginal like environment, potentially safe for vag-
inal tissues, and demonstrates efficacy against the develop-
ment of CAEH.
Although various hydrogels, represented by copolymers of
poly-(ethylene oxide), poly-(propylene oxide), and copolymer
of N-isopropylacrylamide show promising properties for bio-
medical applications, their clinical use has been limited by
their lack of biodegradability, biocompatibility, and physical
stability (31,32). Therefore, there has been a continuing effort
to develop new bio-functional polymers with improved bio-
compatibility and physico-chemical properties. Previously, we
have reported a novel thermo-reversible sol–gel transition
polymer, glycol chitin (GC), which is synthesized by a simple
N-acetylation reaction of glycol chitosan (14). In contrast to
typical sol–gel transition polymers structurally based on syn-
thetic block copolymer structures, GC is an amphiphilic
chitosan-based polymer with good biocompatibility and bio-
degradability. It is one of few polysaccharide-based polymers
autonomously showing a negative thermosensitive sol–gel
transition around body temperature without involvement of
any crosslinking, grafting or blending systems. In this work, we
report for the first time the utilization of GC thermosesitve
polymer as a vaginal drug delivery vehicle for P4. Therefore
we, evaluated the behavior of GC and GC-P4 in vaginal like
environment as described here
Five percent GC of 90% DA used in this study, exhibited
stable gelation near body temperature. Moreover, environ-
mental pH appeared to be another factor influencing GC
Tgel. Since the pKa of the residual amine groups on GC
backbone is ~6.84, ionization of these amines take place at
lower pH inducing the repulsion between polymer chains (33).
Thus, increasing Tgel. On the other hand, association of
polymer chains takes place in a higher pH (~7.2) leading to
a reduction in Tgel. These results indicate the 5% GC at
pH 4.2 forms a gel near body temperature and vaginal pH,
making it a suitable candidate for vaginal application. 5%GC
prepared in pH 4.2 can maintain its physical stability (i.e.
appearance and transparency) after being stored at 4°C for
several months (Figure S8)
We have also confirmed the mucoadhesive ability of GC
based using a rheological synergism evaluation. It was report-
ed that free amine groups on chitosan backbones are the main
driving force for mucoadhesion (16). However, GC used in
this study (≈90% degree of acetylation) only exhibits a fairly
low number of free amine groups when compared to chitosan,
yet still maintained its advantageous mucoadhesive properties
(14). We suggest that thermosensitivity of the hydrogel might
be contributed to its mucoadhesion. Thermosensitivity could
increase the interaction time between GC and the mucinous,
vaginal surface probably providing an enhanced establish-
ment of mucoadhesive forces. Unlike other vaginal formula-
tions, which were occasionally reported to melt and leak at
body temperature, GC maintains its physical stability within
the vaginal environment (2,12). Thus, reducing undesirable
vaginal discharges responsible for vaginal and vulvar irrita-
tions, possible yeast super infection, and ensuring accurate
dosing (3,34).
It is known that some amphiphilic polymers have the ability
to enhance the solubility of hydrophobic drugs by forming
micelle-like aggregates in aqueous media with hydrophobic
domains favoring the partitioning of hydrophobic agents
(14,15). Despite the significant enhancement of the aqueous
solubility of P4 by GC, the enhancement was still in the range
of micrograms and similar to other current methods used to
enhance P4 solubility such as using PEG 400: water (1:1)
mixture. Since the therapeutic effects of P4 are seen in the
milligram dose range, we attempted to increase the amount of
loaded P4 in our system (29,35). Several alternative methods
have been used to enhance the loaded amount of hydrophobic
agents into thermosensitive gels, including dispersing the de-
sired drug to a concentration that exceeds its solubility (9,36).
It was reported that saturating extramicellar channels in poly-
meric hydrogels with drug particles favors the controlled
release of such drug without significantly altering Tgel (36).
Therefore, we developed a dispersion system of 0.1%; (w/v)
P4 into 5% GC at pH 4.2 (GC-P4), which maintained an
acceptable Tgel for mucosal application and thermosensitive
properties of the hydrogel (10).
The GC-P4 system described herein has shown several
favorable rheological characteristics such as stability and
spreadability in vaginal like environment. Here, we showed
that GC-P4 microstructure is more resistant to external stress
and less prone to liquefy under physiological conditions com-
pared to Crinone®, a commercially available P4 gel. In
addition, the preferred shear thinning, non-Newtonian behav-
ior that GC-P4 retained under increasing shear indicates a
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satisfactory distribution across vaginal walls important for an
equal coating for most of the vaginal surface (24). Besides
sheering, there are several other factors in the vagina that can
contribute to gel flow behavior and distribution. For example,
the presence of VFS and SFS can lead to a change in gel-viscosity
through diluting the formulation. Despite the dilution of GC-P4
byVFS, the hydrogel still maintains suitable viscosities. However,
it seems that the viscosity of GC-P4 drastically decreases in the
presence of SFS. It was reported that viscosities of chitosan-based
gels decrease by decreasing the final polymer concentration, due
to reducing intermolecular entanglements between polymer
chains and increasing their free movements (37). Since the dilu-
tion of GC-P4 with SFSwas in 1:1 ratio resembling physiological
volume of semen, we expected to see a significant reduction in
viscosity and gel quality compared to dilution with VFS.
Therefore, we suggest that the application of GC-P4 is not
suitable in the presence of semen such as immediately prior or
shortly after vaginal intercourse due to excessive dilution and
possible leaking of the formulation.
Stability and durability of a formulation in the vagina are
also crucial allowing an effective release time for the loaded
active ingredients (30). After exposure to VFS, GC-P4 showed
gradual reduction in gel weight due to polymer chains disso-
lution (erosion) following initial stage of polymer chain relax-
ation (swelling). These finding suggest that drug release may
be governed by P4 diffusion out of the gel coupled with GC
erosion, typically seen with release mechanisms of drug from
hydrogels (38). The physical presence of GC-P4 hydrogel
in vitro even after 4 h post exposure to VFS might suggest an
extended residence time, due to both its mucoadhesive and
thermosensitive properties. Extended residence times can play
a crucial role in reducing the frequency of administration
required for an effective treatment, and crucial factor to
favorably enhancing patient compliance (9). In this case,
GC-P4’s provided a controlled-release for P4 liberating up
to 50% of the loaded drug within the first four hours post
exposure to vaginal like conditions. Controlled-release systems
usually require less amounts of drug to achieve the desired
therapeutic effect, possibly reducing the cost of therapy (39).
We expect that as the erosion process of GC-P4 hydrogel
continues over time, more drug will be liberated in a con-
trolled manner providing an effective absorption and a steady
P4 tissue concentration, until a phase of rapid release of drug
due to the erosion of the final layer of polymeric gel. Although
the percentage of cumulative P4 released matches the total
percentage of loss in GC-P4 weight, we wanted to exclude the
possibility of P4 inactivation either by the GC system or other
factors. PR-reporter assays show that P4 successfully main-
tains its bioactivity following its released from GC-P4, which
implies that GC provides a compatible medium for P4 with-
out hampering its bioactivity. These results demonstrate that
GC-P4 is indeed a stable hydrogel capable to release biolog-
ically active P4 into the vaginal environment.
Another prerequisite for an effective and safe vaginal for-
mulation is its ability to not interfere with the vaginal mucosal
integrity and the vaginal ecology (40). Vaginal formulations
that are either toxic or non-compatible with the vaginal epi-
thelium can cause local irritation and are associated with
increased inflammation and infection rates, complications
and hence treatment costs (2,13). We showed that GC is safe
to vaginal epithelial tissue and does not cause any apparent
disturbance to the vaginal flora. Higher degrees of acetylation
may be contributing to GC’s superior safety profile respective
to vaginal tissues. Although chitosan is not known to exhibit
increased tissue toxicity, it still may hold potential toxicity
based on its amount of cationic surface groups (41). Charge-
to-charge interactions between cationic materials and anionic
cellular membranes can potentially result in cellular mem-
brane damage (41). Therefore, masking cationic charges by
acetylating amine groups may explain the low toxicity of GC.
A head to head comparison of GC-P4 with the Crinone®, a
commercially available vaginal P4 formulation, using
Clonogenic assay revealed a significant decrease in viable cell
colonies after exposure to Crinone®. This may be due to
some of Crinone’s® ingredients, such as sorbic acid known
to cause tissue irritation (42). Whereas only a slight impact on
colony numbers could be observed after GC-P4 exposure,
implying the relative safety of GC-P4 to vaginal mucosa.
Similar results were found with bacterial growth inhibition
assay, proving the safety of 5%GC andGC-P4 to vaginal flora.
The in vitro safety and biocompatibility of GC-P4 to the
vaginal environment was further confirmed in vivo using a
Female Nu/Nu (6–8 week old) mouse model. Mouse models
are being commonly used as a suitable and economical alter-
native for the preclinical assessment of safety and efficacy of
novel vaginal formulations (43). In direct comparison toGynol
II®, which exhibited significant toxicity to the mouse vaginal
epithelium in vivo presented by signs of chronic irreversible
inflammation, massive cell death of squamous cells, and neu-
trophil infiltration, histopathological evaluation of the mouse
vaginal epithelium after the application of GC-P4 showed
almost no signs of toxicity with only minimal and reversible
inflammation spontaneously resolving (44,45). With a favor-
able outcome of first in vivo studies confirming the safety of
GC-P4 including multiple applications, additional testing for
signs of chronic toxicity needs to be confirmed in future
studies. To assess GC-P4’s efficacy in vivo, an E2 induced EH
mouse model was used. Mice exposed to continuous doses of
E2 developed SEH after around 4 weeks, which then after two
additional weeks will advance to complex atypical EH
(CAEH). No disease progression to CAEH was observed to
occur after 2 weeks of GC-P4 treatment. This finding was
confirmed based on histo-pathological tissue analyses
affirming only signs of SEH without any forms of atypia. On
the other hand, untreated mice indeed progressed from SEH
to CAEH and some cases even advanced all the way to
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borderline EC. Therefore, we suggest that P4 released from
GC-P4 was able to minimize the proliferative action of E2 on
the murine endometrium preventing the progression of SEH
to CAEH or even EC.With the initial very promising efficacy,
additional in vivo animal dose and frequency-finding studies
are still required.
Conclusion
The aim of this work was to improve and optimize the vaginal
delivery of P4 by designing a new bio-functional hydrogel
formulation equipped with thermosensitive and mucoadhesive
characteristics empowering this new formulation to successfully
overcome limitations of currently available vaginal P4 dosage
forms. GC-P4 hydrogel; 5% GC at pH 4.2 loaded with 0.1%
P4, showed a desired sol–gel transition near body temperature
forming and maintaining a stable, gel with desirable flow
behavior in the challenging vaginal environment. Although
viscosity was found to decrease after dilution with certain
biological fluids, GC-P4 gel was still able to maintain a satis-
factory gel status after exposure to VFS. However, GC-P4 gel
administration immediately prior or after vaginal intercourse
may not be recommended due to possibly impacting GC-P4’s
performance and efficacy. GC-P4 gel is capable of prolonged
residence in and exhibits an extended, continued and con-
trolled release of P4. This new formulation has proven to be
safe for application to the vaginal epithelium in vitro as well as
in vivo without causing tissue toxicity or irritation even after
repeated application. Furthermore, initial in vivo efficacy stud-
ies in an EH mouse model revealed the ability of GC-P4 to
prevent the progression of EH from SEH to CAEH. These
results therefore indicate that the GC-P4 formulation is a
promising alternative to current vaginal P4 formulations
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